International experts met in Sydney in 2012 to develop a road map for the management of wet age-related macular degeneration.
Read MoreInternational experts met in Sydney in 2012 to develop a road map for the management of wet age-related macular degeneration.
Read MoreWith a new treatment for wet AMD coming on the market, drug switching between Lucentis and Eylea should be allowed.
Read MoreResearch has revealed Australians significantly underestimate the role of family history in developing macular degeneration.
Read MoreMacular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
Read MoreThe TGA has approved a new drug, Eylea, for the treatment of wet (neovascular) age-related macular degeneration.
Read MoreABC to trial audio description on television to assist people who are blind or visually impaired.
Read MoreDame Judi Dench has revealed a diagnosis of age-related macular degeneration.
Read MoreThe federal government has heard and acknowledged the Foundation’s postcard campaign for increased funding.
Read MoreWe reviewed the results of the CATT study, designed to compare two drugs Lucentis (ranibizumab) and Avastin (bevacizumab) used to treat wet AMD.
Read More